Literature DB >> 26026368

High level PHGDH expression in breast is predominantly associated with keratin 5-positive cell lineage independently of malignancy.

Irina Gromova1, Pavel Gromov1, Naoko Honma2, Sudha Kumar3, David Rimm3, Maj-Lis Møller Talman4, Vera Timmermans Wielenga4, José M A Moreira5.   

Abstract

We have previously reported the 2D PAGE-based proteomic profiling of a prospective cohort of 78 triple negative breast cancer (TNBC) patients, and the establishment of a cumulative TNBC protein database. Analysis of this database identified a number of proteins as being specifically overexpressed in TNBC samples. One such protein was D-3-phosphoglycerate dehydrogenase (Phgdh), a candidate oncogene. We analysed expression of Phgdh in normal and TNBC mammary tissue samples by 2D gel-based proteomics and immunohistochemistry (IHC), and show here that high-level expression of Phgdh in mammary epithelial cells is primarily associated with cell lineage, as we found that Phgdh expression was predominant in CK5-positive cells, normal as well as malignant, thus identifying an association of this protein with the basal phenotype. Quantitative IHC analysis of Phgdh expression in normal breast tissue showed high-level expression of Phgdh in normal CK5-positive mammary epithelial cells, indicating that expression of this protein was not associated with malignancy, but rather with cell lineage. However, proteomic profiling of Phgdh showed it to be expressed in two major protein forms, and that the ratio of expression between these variants was associated with malignancy. Overexpression of Phgdh in CK5-positive cell lineages, and differential protein isoform expression, was additionally found in other tissues and cancer types, suggesting that overexpression of Phgdh is generally associated with CK5 cells, and that oncogenic function may be determined by isoform expression.
Copyright © 2015 Federation of European Biochemical Societies. All rights reserved.

Entities:  

Keywords:  Breast cancer; Phgdh; Proteomics; Serine biosynthesis; “Basal-type” breast cancer

Mesh:

Substances:

Year:  2015        PMID: 26026368      PMCID: PMC5528790          DOI: 10.1016/j.molonc.2015.05.003

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  70 in total

1.  Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

Authors:  José M A Moreira; Teresa Cabezón; Irina Gromova; Pavel Gromov; Vera Timmermans-Wielenga; Isidro Machado; Antonio Llombart-Bosch; Niels Kroman; Fritz Rank; Julio E Celis
Journal:  Mol Oncol       Date:  2010-10-08       Impact factor: 6.603

Review 2.  The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells.

Authors:  R Moll; W W Franke; D L Schiller; B Geiger; R Krepler
Journal:  Cell       Date:  1982-11       Impact factor: 41.582

3.  High level PHGDH expression in breast is predominantly associated with keratin 5-positive cell lineage independently of malignancy.

Authors:  Irina Gromova; Pavel Gromov; Naoko Honma; Sudha Kumar; David Rimm; Maj-Lis Møller Talman; Vera Timmermans Wielenga; José M A Moreira
Journal:  Mol Oncol       Date:  2015-05-14       Impact factor: 6.603

Review 4.  Targeting cancer metabolism: a therapeutic window opens.

Authors:  Matthew G Vander Heiden
Journal:  Nat Rev Drug Discov       Date:  2011-08-31       Impact factor: 84.694

5.  Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.

Authors:  C Leal; R Henrique; P Monteiro; C Lopes; M J Bento; C P De Sousa; P Lopes; S Olson; M D Silva; D L Page
Journal:  Hum Pathol       Date:  2001-05       Impact factor: 3.466

6.  Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.

Authors:  Emilia Montagna; Patrick Maisonneuve; Nicole Rotmensz; Giuseppe Cancello; Monica Iorfida; Alessandra Balduzzi; Viviana Galimberti; Paolo Veronesi; Alberto Luini; Giancarlo Pruneri; Luca Bottiglieri; Mauro G Mastropasqua; Aron Goldhirsch; Giuseppe Viale; Marco Colleoni
Journal:  Clin Breast Cancer       Date:  2012-10-24       Impact factor: 3.225

Review 7.  MYC-induced cancer cell energy metabolism and therapeutic opportunities.

Authors:  Chi V Dang; Anne Le; Ping Gao
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

8.  Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

Authors:  Maurizio Scaltriti; Federico Rojo; Alberto Ocaña; Judit Anido; Marta Guzman; Javier Cortes; Serena Di Cosimo; Xavier Matias-Guiu; Santiago Ramon y Cajal; Joaquin Arribas; José Baselga
Journal:  J Natl Cancer Inst       Date:  2007-04-18       Impact factor: 13.506

Review 9.  Non-operative breast pathology: apocrine lesions.

Authors:  C A Wells; G A El-Ayat
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

Review 10.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

View more
  17 in total

Review 1.  Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?

Authors:  Nissim Hay
Journal:  Nat Rev Cancer       Date:  2016-09-16       Impact factor: 60.716

2.  High level PHGDH expression in breast is predominantly associated with keratin 5-positive cell lineage independently of malignancy.

Authors:  Irina Gromova; Pavel Gromov; Naoko Honma; Sudha Kumar; David Rimm; Maj-Lis Møller Talman; Vera Timmermans Wielenga; José M A Moreira
Journal:  Mol Oncol       Date:  2015-05-14       Impact factor: 6.603

Review 3.  The hallmarks of cancer metabolism: Still emerging.

Authors:  Natalya N Pavlova; Jiajun Zhu; Craig B Thompson
Journal:  Cell Metab       Date:  2022-02-04       Impact factor: 27.287

Review 4.  3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment.

Authors:  Mingxue Li; Canrong Wu; Yueying Yang; Mengzhu Zheng; Silin Yu; Jinhui Wang; Lixia Chen; Hua Li
Journal:  Cell Oncol (Dordr)       Date:  2021-03-18       Impact factor: 6.730

5.  High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.

Authors:  Jinhong Zhu; Jianqun Ma; Xudong Wang; Tianjiao Ma; Shu Zhang; Wei Wang; Xiaoyu Zhou; Jiahai Shi
Journal:  Transl Oncol       Date:  2016-12       Impact factor: 4.243

6.  A proteomic approach for the identification of biomarkers in endometrial cancer uterine aspirate.

Authors:  Blendi Ura; Lorenzo Monasta; Giorgio Arrigoni; Cinzia Franchin; Oriano Radillo; Isabel Peterlunger; Giuseppe Ricci; Federica Scrimin
Journal:  Oncotarget       Date:  2017-11-30

7.  Disruption of the EZH2/miRNA/β-catenin signaling suppresses aerobic glycolysis in glioma.

Authors:  Yingyi Wang; Min Wang; Wenjin Wei; Dongfeng Han; Xincheng Chen; Qi Hu; Tianfu Yu; Ning Liu; Yongping You; Junxia Zhang
Journal:  Oncotarget       Date:  2016-08-02

Review 8.  Molecular Portrait of the Normal Human Breast Tissue and Its Influence on Breast Carcinogenesis.

Authors:  Madalin Marius Margan; Andreea Adriana Jitariu; Anca Maria Cimpean; Cristian Nica; Marius Raica
Journal:  J Breast Cancer       Date:  2016-06-24       Impact factor: 3.588

9.  Phosphoglycerate dehydrogenase is a novel predictor for poor prognosis in gastric cancer.

Authors:  Yun Xian; Shu Zhang; Xudong Wang; Jin Qin; Wei Wang; Han Wu
Journal:  Onco Targets Ther       Date:  2016-09-07       Impact factor: 4.147

10.  Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer.

Authors:  Irina Gromova; Sofia Svensson; Pavel Gromov; José M A Moreira
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.